Time course of reverse remodeling of the left ventricle during support with a left ventricular assist device

Madigan, John D.; Barbone, Alessandro; Choudhri, Asim F.; Morales, David L.S.; Cai, Bolin; Öz, Mehmet C.; Burkhoff, Daniel

doi:10.1067/mtc.2001.112632

Cited by 144 publications

(120 citation statements)

References 9 publications

(16 reference statements)

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, LVADs have been shown to lead to partial normalization of myocardial structure and function, including increased ␤-AR responsiveness (30); decreased myocyte volume (40), width (41), and diameter (22); and improved myocyte contractility (10) in a process termed "reverse remodeling." We were the first to report both global and etiology-specific differential gene expression using paired tissue samples from patients in end-stage HF and following LVAD-mediated reverse remodeling, followed by several other reports (4,5,15,24).…”

mentioning

confidence: 99%

Identification of Nogo as a novel indicator of heart failure

Bullard

Protack

Aguilar

et al. 2008

Physiological Genomics

View full text Add to dashboard Cite

Numerous genetically engineered animal models of heart failure (HF) exhibit multiple characteristics of human HF, including aberrant β-adrenergic signaling. Several of these HF models can be rescued by cardiac-targeted expression of the Gβγ inhibitory carboxy-terminus of the β-adrenergic receptor kinase (βARKct). We recently reported microarray analysis of gene expression in multiple animal models of HF and their βARKct rescue, where we identified gene expression patterns distinct and predictive of HF and rescue. We have further investigated the muscle LIM protein knockout model of HF (MLP−/−), which closely parallels human dilated cardiomyopathy disease progression and aberrant β-adrenergic signaling, and their βARKct rescue. A group of known and novel genes was identified and validated by quantitative real-time PCR whose expression levels predicted phenotype in both the larger HF group and in the MLP−/− subset. One of these novel genes is herein identified as Nogo, a protein widely studied in the nervous system, where it plays a role in regeneration. Nogo expression is altered in HF and normalized with rescue, in an isoform-specific manner, using left ventricular tissue harvested from both animal and human subjects. To investigate cell type-specific expression of Nogo in the heart, immunofluorescence and confocal microscopy were utilized. Nogo expression appears to be most clearly associated with cardiac fibroblasts. To our knowledge, this is the first report to demonstrate the relationship between Nogo expression and HF, including cell-type specificity, in both mouse and human HF and phenotypic rescue.

show abstract

mentioning

confidence: 99%

Identification of Nogo as a novel indicator of heart failure

Bullard

Protack

Aguilar

et al. 2008

Physiological Genomics

View full text Add to dashboard Cite

show abstract

“…7,13,[20][21][22] In this study, the LVEF increased significantly during PF LVAD support compared with CF devices. Although clinical backgrounds were not necessarily matched completely, some authors showed more volume unloading with PF devices, 13,14 while others showed that a PF pump was better than a CF pump considering the improvement in LVEF or explantation in the clinical setting.…”

Section: Disclosuresmentioning

confidence: 71%

Advantage of Pulsatility in Left Ventricular Reverse Remodeling and Aortic Insufficiency Prevention During Left Ventricular Assist Device Treatment

Imamura

Kinugawa

Nitta

et al. 2015

Circ J

View full text Add to dashboard Cite

“…Usually, left ventricular assist devices are employed as a bridge to heart transplant [6]. It follows that they should be discontinued once one is no longer a candidate for transplant.…”

Section: Informed Refusal Of Treatmentmentioning

confidence: 99%